FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 312:1422-1428 May 30, 1985 Number 22 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We tested HemoQuant, a quantitative assay of fecal blood based on the fluorescence of heme-derived porphyrin, in 106 healthy volunteers, 170 patients with gastrointestinal symptoms but with normal diagnostic studies, 44 patients with gastrointestinal cancer, 75 patients with benign polyps, and 374 patients with a variety of other benign gastrointestinal lesions, including ulcers and erosions. In 98 per cent of the healthy volunteers, fecal hemoglobin concentrations were less than 2 mg per gram of stool. Levels were similarly low in stools from patients with symptoms and normal studies and in patients with relatively minor benign lesions. Within these groups, levels were slightly higher in those who had ingested red meat or aspirin. The fecal hemoglobin concentration was higher in patients with gastrointestinal cancer than in any other group, and 97 per cent of those with colorectal cancer had levels above 2 mg per gram. The sensitivity of HemoQuant was significantly greater than that of the guaiac test Hemoccult, particularly when heme was degraded or stools were dry. Intestinal degradation of heme to porphyrin can be measured separately by HemoQuant, and was greater when bleeding was from proximal lesions rather than distal ones. We conclude that HemoQuant is a more sensitive measure of gastrointestinal bleeding than Hemoccult, and that its capacity to measure degraded heme may be useful in indicating the anatomic site of bleeding.

This article has been cited by other articles:

• Thompson, J. L., Hamner, C. E., Potter, D. D., Lewin, M., Sundt, T. M., Schaff, H. V. (2007). Melagatran for thromboprophylaxis after mechanical valve implantation: Results in a heterotopic porcine model. J. Thorac. Cardiovasc. Surg. 134: 359-365 [Abstract] [Full Text]  
• Harewood, G. C., McConnell, J. P., Harrington, J. J., Mahoney, D. W., Ahlquist, D. A. (2002). Detection of Occult Upper Gastrointestinal Tract Bleeding: Performance Differences in Fecal Occult Blood Tests. Mayo Clin. Proc. 77: 23-28 [Abstract]  
• Ladabaum, U., Chopra, C. L., Huang, G., Scheiman, J. M., Chernew, M. E., Fendrick, A. M. (2001). Aspirin as an Adjunct to Screening for Prevention of Sporadic Colorectal Cancer: A Cost-Effectiveness Analysis. ANN INTERN MED 135: 769-781 [Abstract] [Full Text]  
• Rockey, D. C. (1999). Occult Gastrointestinal Bleeding. NEJM 341: 38-46 [Full Text]  
• Rockey, D. C., Koch, J., Cello, J. P., Sanders, L. L., McQuaid, K. (1998). Relative Frequency of Upper Gastrointestinal and Colonic Lesions in Patients with Positive Fecal Occult-Blood Tests. NEJM 339: 153-159 [Abstract] [Full Text]  
• Miller, M. P., Stanley, T. V. (1988). Results of a Mass Screening Program for Colorectal Cancer. Arch Surg 123: 63-65 [Abstract]